MERCK & CO., INC.
Ownership & governance
Executives 5Directors 10Avg age 63Avg tenure 11.1y
RD
Robert Davis
Chief Executive Officer
Age 59Since 2021-06-30Profile →
+14
Executives5
RD
Robert Davis→
Chief Executive Officer
Age 59Since 2021-06-30
CL
Caroline Litchfield
Director of Finance/CFO
Age 57Since 2021-03-31
MG
Marjorie Green
Chief Tech/Sci/R&D Officer
——
DW
Dave Williams
Chief Tech/Sci/R&D Officer
Age 57Since 2020-07-31
JR
Joseph Romanelli
Investor Relations Contact
Age 52Since 1995-12-31
Board of directors10
TG
Tom Glocer→
Director/Board Member
Age 65Since 2007-11-26
PR
Patricia Russo→
Director/Board Member
Age 73Since 1995-08-31
RD
Robert Davis→
Chairman
Age 59Since 2022-11-30
PC
Pamela Craig→
Director/Board Member
Age 69Since 2015-08-31
PR
Paul Rothman→
Director/Board Member
Age 68Since 2015-08-31
IT
Inge Thulin→
Director/Board Member
Age 71Since 2018-02-28
MC
Mary Coe→
Director/Board Member
Age 59Since 2019-03-17
KW
Kathy Warden→
Director/Board Member
Age 54Since 2020-03-15
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| BlackRock Advisors LLC | 6.707 % | 165,654,931 |
| Vanguard Capital Management LLC | 6.518 % | 160,987,624 |
| STATE STREET CORPORATION | 4.831 % | 119,325,673 |
| Wellington Trust Co., NA | 3.414 % | 84,314,971 |
| Vanguard Portfolio Management LLC | 2.725 % | 67,304,305 |
Catalog · 2026-07-09
Registry officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Robert Davis | Chairman | 2022-11-30 | - |
| Christine Seidman | Director/Board Member | 2020-03-15 | - |
| Inge Thulin | Director/Board Member | 2018-02-28 | - |
| Kathy Warden | Director/Board Member | 2020-03-15 | - |
| Mary Coe | Director/Board Member | 2019-03-17 | - |
| Pamela Craig | Director/Board Member | 2015-08-31 | - |
| Patricia Russo | Director/Board Member | 1995-08-31 | - |
| Paul Rothman | Director/Board Member | 2015-08-31 | - |
Registry · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| MSD Sharp & Dohme GmbH | Pharmaceuticals: Major |
| Merck Sharp & Dohme LLC | Pharmaceuticals: Major |
| Merck Sharp & Dohme LLC | Pharmaceuticals: Major |
| MSD Finance BV | Miscellaneous |
| Merck Sharp & Dohme Finance Europe Ltd. | Miscellaneous Commercial Services |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 158.64Range 105–186Analysts 25
105Mean 158.64186
- Strong buy 5
- Buy 14
- Hold 8
Broker actions40 of 375
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Neutral | 145 | 2026-10-12 |
| RBC Capital | Maintained | Sector Perform | 145 | 2026-10-12 |
| Cantor Fitzgerald | Maintained | Neutral | 145 | 2026-10-08 |
| Morgan Stanley | Maintained | Overweight | 177 | 2026-10-07 |
| JP Morgan | Maintained | Overweight | 165 | 2026-10-05 |
| Scotiabank | Maintained | Sector Outperform | 180 | 2026-09-29 |
| HSBC | Maintained | Buy | 172 | 2026-09-10 |
| Leerink Partners | Maintained | Outperform | 161 | 2026-09-09 |
| Guggenheim | Maintained | Buy | 170 | 2026-09-08 |
| Wells Fargo | Maintained | Overweight | 170 | 2026-09-04 |
| Wolfe Research | Maintained | Outperform | 180 | 2026-08-25 |
| Argus Research | Maintained | Buy | 170 | 2026-08-25 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.